Skip to main content

Research Repository

Advanced Search

Outputs (58)

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. (2023)
Journal Article
Velikova, G., Morden, J. P., Haviland, J. S., Emery, C., Barrett-Lee, P., Earl, H., …Cameron, D. (in press). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, S1470-2045(23)00460-6. https://doi.org/10.1016/S1470-2045%2823%2900460-6

Adjuvant chemotherapy for patients with early breast cancer improves outcomes but its toxicity affects patients' quality of life (QOL). The UK TACT2 trial investigated whether accelerated epirubicin improves time to recurrence and if oral capecitabin... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial..

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. (2023)
Journal Article
Coles, C. E., Haviland, J. S., Kirby, A. M., Griffin, C. L., Sydenham, M. A., Titley, J. C., …Bliss, J. M. (in press). Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet, 401(10394), 2124-2137. https://doi.org/10.1016/S0140-6736%2823%2900619-0

A tumour-bed boost delivered after whole-breast radiotherapy increases local cancer-control rates but requires more patient visits and can increase breast hardness. IMPORT HIGH tested simultaneous integrated boost against sequential boost with the ai... Read More about Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial..

Hypofractionation: The standard for external beam breast irradiation (2023)
Journal Article
Brunt, A. M., & Haviland, J. S. (2023). Hypofractionation: The standard for external beam breast irradiation. Breast, 69, 410 - 416. https://doi.org/10.1016/j.breast.2023.04.006

This overview provides the historical perspective of external beam breast hypofractionation over the last 50 years. It highlights the serious harm suffered by patients with breast cancer in the 1970's and 1980's because of new hypofractionation regim... Read More about Hypofractionation: The standard for external beam breast irradiation.

Hypofractionation: The standard for external beam breast irradiation (2023)
Journal Article
Brunt, A. M., & Haviland, J. S. (2023). Hypofractionation: The standard for external beam breast irradiation. Breast, 69, 410-416. https://doi.org/10.1016/j.breast.2023.04.006

This overview provides the historical perspective of external beam breast hypofractionation over the last 50 years. It highlights the serious harm suffered by patients with breast cancer in the 1970's and 1980's because of new hypofractionation regim... Read More about Hypofractionation: The standard for external beam breast irradiation.

Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2023)
Dataset
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Dataset]. https://doi.org/10.1158/1078-0432.c.6532623.v1

Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included n... Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2023)
Dataset
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., M. Shaaban, A., …Bliss, J. M. (2023). Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. [Dataset]. https://doi.org/10.1158/1078-0432.c.6532623

Purpose: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. Patients and Methods: This randomized phase II, two-part, multicenter trial included n... Read More about Data from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity (2023)
Journal Article
Fernando, I., Lax, S., Bowden, S., Ahmed, I., Steven, J., Churn, M., …Rea, D. (2023). Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity. Clinical Oncology, 35(6), 397-407. https://doi.org/10.1016/j.clon.2023.03.007

Aims SECRAB was a prospective, open-label, multicentre, randomised phase III trial comparing synchronous to sequential chemoradiotherapy (CRT). Conducted in 48 UK centres, it recruited 2297 patients (1150 synchronous and 1146 sequential) between 2 J... Read More about Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.

Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. (2023)
Journal Article
Oswald, A., Symeonides, S., Wheatley, D., Chan, S., Brunt, A., McAdam, K., …Cameron, D. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment, 199, https://doi.org/10.1007/s10549-023-06873-8

PURPOSE: The development of oestrogen resistance is a major challenge in managing hormone-sensitive metastatic breast cancer. Saracatinib (AZD0530), an oral Src kinase inhibitor, prevents oestrogen resistance in animal models and reduces osteoclast a... Read More about Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study..

Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. (2022)
Journal Article
Glynn, D., Bliss, J., Brunt, A. M., Coles, C. E., Wheatley, D., Haviland, J. S., …Griffin, S. (2022). Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Research and Treatment, 197, 405-416. https://doi.org/10.1007/s10549-022-06802-1

PURPOSE: We estimated the cost-effectiveness of 4 radiotherapy modalities to treat early breast cancer in the UK. In a subgroup of patients eligible for all modalities, we compared whole-breast (WB) and partial breast (PB) radiotherapy delivered in e... Read More about Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis..

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results (2022)
Journal Article
Bundred, N., Porta, N., Brunt, A. M., Cramer, A., Hanby, A., Shaaban, A. M., …Bliss, J. M. (2022). Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clinical Cancer Research, 28(7), 1323 - 1334. https://doi.org/10.1158/1078-0432.CCR-21-3177

PURPOSE: EPHOS-B aimed to determine whether perioperative anti-HER2 therapy inhibited proliferation and/or increased apoptosis in HER2-positive breast cancer. PATIENTS AND METHODS: This randomized phase II, two-part, multicenter trial included newly... Read More about Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results.

The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial (2022)
Journal Article
Ingram, J., Beasant, L., Benson, J., Brunt, A. M., Maxwell, A., Harvey, J. R., …Winters, Z. (2022). The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial. Pilot and Feasibility Studies, 8(1), Article ARTN 46. https://doi.org/10.1186/s40814-022-01007-1

Background A multicentre feasibility trial (MIAMI), comparing outcomes and quality of life of women with multiple ipsilateral breast cancer randomised to therapeutic mammoplasty or mastectomy, was conducted from September 2018 to March 2020. The MIA... Read More about The challenge of equipoise: qualitative interviews exploring the views of health professionals and women with multiple ipsilateral breast cancer on recruitment to a surgical randomised controlled feasibility trial.

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. (2021)
Journal Article
Meattini, I., Becherini, C., Boersma, L., Kaidar-Person, O., Nader Marta, G., Montero, A., …Coles, C. E. (2022). European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncology, 23(1), e21 - e31. https://doi.org/10.1016/S1470-2045%2821%2900539-8

High-quality randomised clinical trials testing moderately fractionated breast radiotherapy have clearly shown that local control and survival is at least as effective as with 2 Gy daily fractions with similar or reduced normal tissue toxicity. Fewer... Read More about European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer..

Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation (2021)
Journal Article
Brunt, A. M., Haviland, J. S., Kirby, A. M., Somaiah, N., Wheatley, D. A., Bliss, J. M., & Yarnold, J. R. (2021). Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clinical Oncology, 33(7), 430-439. https://doi.org/10.1016/j.clon.2021.04.016

INTRODUCTION: The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in 4000 patients. We discuss concerns raised by the radiotherapy community in rel... Read More about Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation.

When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management (2021)
Journal Article
Obeng-Gyasi, S., Coles, C. E., Jones, J., Sacks, R., Lightowlers, S., Bliss, J. M., …Kalinsky, K. (2021). When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. American Society of Clinical Oncology educational book, 41(41), e79-e89. https://doi.org/10.1200/edbk_320691

In the care of patients with operable breast cancer, there has been a shift toward increasing use of neoadjuvant therapy. There are benefits to neoadjuvant therapy, such as monitoring for response, as well as an increased rate of breast conservation... Read More about When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management.

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial (2021)
Journal Article
Hoskin, P., Popova, B., Schofield, O., Brammer, C., Robinson, M., Brunt, A. M., …Kirkwood, A. A. (2021). 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncology, 22(3), 332-340. https://doi.org/10.1016/S1470-2045%2820%2930686-0

BACKGROUND: The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4 Gy in two fractions (low-dose radiation). METHODS: FoRT (Follicular Radioth... Read More about 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial.

Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer (2020)
Report
Brunt, A. M., Haviland, J. S., Sydenham, M., Agrawal, R. K., Algurafi, H., Alhasso, A., …Yarnold, J. R. (2020). Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer

PURPOSE: Previous studies of hypofractionated adjuvant whole-breast radiotherapy for early breast cancer established a 15- or 16-fraction (fr) regimen as standard. The FAST Trial (CRUKE/04/015) evaluated normal tissue effects (NTE) and disease outcom... Read More about Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer.

Breast Cancer Management Guidelines During COVID-19 Pandemic (2020)
Journal Article
Gowda S, M., Katherine Kabeer, K., Jafferbhoy, S., Marla, S., Soumian, S., Misra, V., …Brunt, A. M. (2020). Breast Cancer Management Guidelines During COVID-19 Pandemic. Indian Journal of Surgery, 82, 251-258. https://doi.org/10.1007/s12262-020-02466-7

The coronavirus disease (COVID-19) pandemic in 2020 has brought about complex challenges in healthcare delivery. With the new rules of lockdown and social distancing and with resources diverted to the management of COVID-19, there are difficulties in... Read More about Breast Cancer Management Guidelines During COVID-19 Pandemic.

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial (2020)
Journal Article
Brunt, A. M., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., …Management Group, F. T. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet, 395(10237), 1613 - 1626. https://doi.org/10.1016/S0140-6736%2820%2930932-6

BACKGROUND: We aimed to identify a five-fraction schedule of adjuvant radiotherapy (radiation therapy) delivered in 1 week that is non-inferior in terms of local cancer control and is as safe as an international standard 15-fraction regimen after pri... Read More about Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial (2020)
Journal Article
King, M. T., Link, E. K., Whelan, T. J., Olivotto, I. A., Kunkler, I., Westenberg, A. H., …Lavery, B. (2020). Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncology, 21(5), 685-698. https://doi.org/10.1016/s1470-2045%2820%2930085-1

Background BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with non-low-risk ductal carcinoma in situ following breast-conserving surgery and w... Read More about Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial (2019)
Journal Article
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Murray Brunt, A., Nemsadze, G., …C. Turner, N. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38(5), 423 - 433. https://doi.org/10.1200/JCO.19.00368

PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is frequently activated in triple-negative breast cancer (TNBC). The AKT inhibitor capivasertib has shown preclinical activity in TNBC models, and drug sensitivity has been assoc... Read More about Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.

Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial (2019)
Journal Article
Fernando, I. N., Bowden, S. J., Herring, K., Brookes, C. L., Ahmed, I., Marshall, A., …Rea, D. W. (2020). Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. Radiotherapy and Oncology, 142, 52-61. https://doi.org/10.1016/j.radonc.2019.10.014

BACKGROUND: The optimal sequence of adjuvant chemotherapy and radiotherapy for breast cancer is unknown. SECRAB assesses whether local control can be improved without increased toxicity. METHODS: SECRAB was a prospective, open-label, multi-centre, ph... Read More about Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial.

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer (2019)
Journal Article
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5(11), 1556 - 1556. https://doi.org/10.1001/jamaoncol.2019.2526

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating... Read More about Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial (2019)
Journal Article
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., …Peoples, G. E. (2019). Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. Clinical Cancer Research, 25(14), 4248-4254. https://doi.org/10.1158/1078-0432.ccr-18-2867

long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma (2019)
Journal Article
Hoskin, P., Kirkwood, A., Popova, B., Schofield, O., Brammer, C., Robinson, M., …Clifton-Hadley, L. (2019). long term follow-up of FoRT: a phase 3 multi-center prospective randomized trial of radiation therapy for follicular and marginal zone lymphoma. Hematological Oncology, 37(S2), 219 - 220. https://doi.org/10.1002/hon.34_2630

Supplement article.

16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654) (2019)
Journal Article
Winters, Z., Roberts, N., McCartan, N., Potyka, I., Brunt, M., Maxwell, A., …Williams, N. (2019). 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654). EJSO - European Journal of Surgical Oncology, 45(5), 881. https://doi.org/10.1016/j.ejso.2019.01.202

Background: Oncological safety of treating multiple ipsilateral breast cancers (MIBC) using therapeutic mammoplasty (TM) compared to mastectomy remains uncertain. A National Institute for Health Research (NIHR) - funded MIAMI feasibility phase random... Read More about 16. Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomized controlled feasibility trial called MIAMI UK (NCT03514654).

Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK (2019)
Journal Article
Brunt. (2019). Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility trial called MIAMI UK. Annals of Surgical Oncology, 58 - 60

Meeting abstract, from the 20th Annual Meeting of the American-Society-of-Breast-Surgeons Conference, Dallas, Texas, 30 Apr - 5 May, 2019.

Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003) (2018)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Haviland, J., Titley, J., Benstead, K., …Yarnold, J. (2018, December). Dose escalated simultaneous integrated boost radiotherapy for women treated by breast conservation surgery for early breast cancer: 3-year adverse effects in the IMPORT HIGH trial (CRUK/06/003). Presented at 2018 San Antonio Breast Cancer Symposium, San Antonio, Texas, USA

Meeting abstract (Abstract GS4-05 from 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas).

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015) (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Algurafi, H., Alhasso, A., Bliss, P., …Yarnold, J. (2018). FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology - Biology - Physics, 102(5), 1603 -1604. https://doi.org/10.1016/j.ijrobp.2018.08.049

Conference abstract.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial (2018)
Journal Article
Velikova, G., Jane Williams, L., Willis, S., Michael Dixon, J., Loncaster, J., Hatton, M., …Yuille, F. (2018). Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, 19(11), 1516 - 1529. https://doi.org/10.1016/s1470-2045%2818%2930515-1

Background Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radio... Read More about Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018)
Journal Article
Corrie, P., Marshall, A., Nathan, P., Lorigan, P., Gore, M., Tahir, S., …Coltart, R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 29(8), 1843 -1852. https://doi.org/10.1093/annonc/mdy229

Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recur... Read More about Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., …Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. (2018)
Journal Article
Winters, Z. E., Horsnell, J., Elvers, K. T., Maxwell, A. J., Jones, L. J., Shaaban, A. M., …Brunt, A. M. (2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 2(4), 162 - 174. https://doi.org/10.1002/bjs5.53

Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC) breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is uncertain. Inconsistencies relate to definitions, in... Read More about Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers..

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., …Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Paper presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.

MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer (2017)
Presentation / Conference
Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., …Cortes Castan, J. (2017, December). MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. Paper presented at 2017 San Antonio Breast Cancer Symposium, San Antonio, Texas

Background: Resistance to endocrine therapy remains a major clinical challenge with aberrant PI3K/ mTOR pathway activation being one of the main drivers. Randomised clinical trials have demonstrated a substantial benefit of adding everolimus to endoc... Read More about MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer.

Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. (2017)
Journal Article
Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., …Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. The Lancet, 390(10099), 1048 - 1060. https://doi.org/10.1016/S0140-6736%2817%2931145-5

BACKGROUND: Local cancer relapse risk after breast conservation surgery followed by radiotherapy has fallen sharply in many countries, and is influenced by patient age and clinicopathological factors. We hypothesise that partial-breast radiotherapy r... Read More about Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial..

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial (2017)
Journal Article
Cameron, D., Morden, J. P., Canney, P., Velikova, G., Coleman, R., Bartlett, J., …Bliss, J. M. (2017). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, 18(7), 929 - 945. https://doi.org/10.1016/S1470-2045%2817%2930404-7

Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve time to tumour recurrence... Read More about Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial.

Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial (2017)
Presentation / Conference
Coles, C., Griffin, C., Kirby, A., Agrawal, R., Alhasso, A., Bhattacharya, I., …Bliss, J. (2017, May). Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Paper presented at ESTRO 36, Vienna, Austria

Conference abstract. Part of special issue: ESTRO 36, May 5-9, 2017, Vienna, Austria.

Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose? (2017)
Report
Price, L., & Brunt, A. M. (2017). Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?

Trastuzumab (Herceptin) is used in neoadjuvant, adjuvant and metastatic breast cancer. Infusion reactions are a common side effect most of which are mild and easily managed, anaphylaxis occurs rarely. The summary of product characteristics recommends... Read More about Trastuzumab infusion reactions in breast cancer. Should we routinely observe after the first dose?.

Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial (2016)
Journal Article
Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., …Bliss, J. M. (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-118. https://doi.org/10.1016/j.radonc.2016.02.027

BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undert... Read More about Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.

Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer (2016)
Journal Article
Brunt, A. M., Lupton, S., Thorley, K., Pearce, L., & Handley, J. (2016). Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer. Reports of Practical Oncology and Radiotherapy, 21(3), 219-224. https://doi.org/10.1016/j.rpor.2016.02.004

Aim A comparison of techniques, CT planning of the supraclavicular fossa and field based simulation. We highlight CT planned SCF radiotherapy which would be useful for a centre introducing the technique. Background Development of radiotherapy te... Read More about Comparison of CT-volumed supraclavicular fossa radiotherapy planning and conventional simulator-planned defined by bony landmarks for early breast cancer.

Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003) (2016)
Presentation / Conference
Coles, C., Agrawal, R., Ah-See, M., Algurafi, H., Alhasso, A., Brunt, A., …Bliss, J. (2016, March). Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003). Paper presented at 10th European Breast Cancer Conference (EBCC-10)

Background: IMPORT LOW is a randomised, multi-centre phase III trial testing partial breast radiotherapy (RT) using intensity modulated RT in women with low risk early stage breast cancer, for whom late complications of RT are the dominant hazard rat... Read More about Partial breast radiotherapy for women with early breast cancer: First results of local recurrence data for IMPORT LOW (CRUK/06/003).

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (2013)
Journal Article
RD Johnston, S., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., …investigators, S. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, 14(10), 989-998. https://doi.org/10.1016/S1470-2045%2813%2970322-X